API HPAPI Industry Fact Sheet 2012
1
Fact Sheet – API/HPAPI Industry 2012 Global: The global API market was $101 billion in 2010, expected to grow at rate of 7.9%, reaching around $136 billion by 2015 Major Markets North America – 32%, Europe- 31% and Asia – 26% Major Segments Merchant API Market - $ 39 billion & API produced and used by companies itself - $ 62 billion Merchant Market • Generic API – 48.7%, Branded API – 51.3% Notable Trends Increasing influence of API participants, increasing emphasis on High Potency API’s, growth of generic API market compared to Branded API market India: • The Indian bulk drug market during 2010 was $ 8billion, It is expected to grow to $ 20.7 billion by 2015 at increased CAGR of 21 % Growth Drivers: Pressures of patent expiry and outsourcing of production by Global Pharma companies Growing credibility of Indian manufacturers Increasing penetration of generics in the regulated markets (especially EU and Japan) Increase in lifestyle related and other diseases Major Issues: The increase in number of drugs going off patent till 2012, Lack of government support for bulk drugs industry, the strict environmental laws put up by government, increase in labor and labor costs associated with increase in production. HPAPI Market: Classification – 1) Synthesis route, 2) Customer base Global: The global HPAPI market is valued at US $8.9 billion in 2011, growing at a CAGR of 8.3% is projected to reach US $12.18 in 2015 Major Markets: North America, Europe, Asia Pacific Major Segments: Oncology – 59%, Hormones – 19%, Glaucoma-7 % India: Indian HPAPI market is valued at Rs.365 crore and is growing at rate of 14.9% reaching Rs.608 crores in 2015 Major Segments: Prostaglandins, Steroids, Hormones and Oncologicals. Major Issue: High Capital investment, Complexity in production Source: • www.pharmtech.com, www.reuters.com/article-14.02.2012, www.prnewswire.com, www.expresspharmaonline.com-15.12.2011, www.pharmaintellect.com,www.specchemonline.com, www.gbiresearch.com 2010, Interlink insight Apr – Mar 2012, www.contractpharma.com/issues - 01.2012 • Interlink Knowledge Cell
-
Upload
interlink-marketing-consultancy-pvt-ltd -
Category
Documents
-
view
17 -
download
0
description
Interlink Marketing Consultancy provides expert help on query. Find ways to business growth strategy and competency development. Promotes future of healthcare in India.
Transcript of API HPAPI Industry Fact Sheet 2012
Fact Sheet – API/HPAPI Industry
2012
Global:
The global API market was $101 billion in 2010, expected to grow at rate of 7.9%, reaching
around $136 billion by 2015
Major Markets
North America – 32%, Europe- 31% and Asia – 26%
Major Segments
Merchant API Market - $ 39 billion & API produced and used by companies itself - $ 62 billion
Merchant Market
• Generic API – 48.7%, Branded API – 51.3%
Notable Trends
Increasing influence of API participants, increasing emphasis on High Potency API’s, growth of
generic API market compared to Branded API market
India:
• The Indian bulk drug market during 2010 was $ 8billion, It is expected to grow to $ 20.7
billion by 2015 at increased CAGR of 21 %
Growth Drivers:
Pressures of patent expiry and outsourcing of production by Global Pharma companies
Growing credibility of Indian manufacturers
Increasing penetration of generics in the regulated markets (especially EU and Japan)
Increase in lifestyle related and other diseases
Major Issues: The increase in number of drugs going off patent till 2012, Lack of government
support for bulk drugs industry, the strict environmental laws put up by government, increase in
labor and labor costs associated with increase in production.
HPAPI Market:
Classification – 1) Synthesis route, 2) Customer base
Global: The global HPAPI market is valued at US $8.9 billion in 2011, growing at a CAGR of 8.3% is
projected to reach US $12.18 in 2015
Major Markets: North America, Europe, Asia Pacific
Major Segments: Oncology – 59%, Hormones – 19%, Glaucoma-7 %
India: Indian HPAPI market is valued at Rs.365 crore and is growing at rate of 14.9% reaching
Rs.608 crores in 2015
Major Segments: Prostaglandins, Steroids, Hormones and Oncologicals.
Major Issue: High Capital investment, Complexity in production
Source:
• www.pharmtech.com, www.reuters.com/article-14.02.2012, www.prnewswire.com, www.expresspharmaonline.com-15.12.2011,
www.pharmaintellect.com,www.specchemonline.com, www.gbiresearch.com 2010, Interlink insight Apr – Mar 2012,
www.contractpharma.com/issues - 01.2012
• Interlink Knowledge Cell
